Search global stocks & ETFs...Ctrl K
Learn Mode
CPH.TO
Stock Profile
08-05
Recommended Metric
Score Card
Explore Scores Tab
4.36
Very Good
Valuation Model
Key Score
4.00
Good
Management
5.00
Very Good
Growth
5.00
Very Good
Profitability
5.00
Very Good
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Buyback Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
CA$16.77
Baseline
High
CA$22.37
▲
33.36%
Avg
CA$20.84
▲
24.28%
Low
CA$19.19
▲
14.43%
Analyst Ratings based on 9 Analysts
Strong Buy
111%
Buy
556%
Hold
333%
Sell
000%
Strong Sell
000%
Cipher Pharmaceuticals, Inc. engages in a diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario and currently employs 43 full-time employees. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.Read More
Stock News
View All Updates
Why The Cipher Pharmaceuticals (TSX:CPH) Story Is Shifting As Analysts Lift Valuation Targets
1wYahoo
Results: Cipher Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
3wYahoo
Cipher Pharmaceuticals Inc. (CPH:CA) Q1 2026 Earnings Call Transcript
4wSeekingAlpha
Cipher Pharmaceuticals Inc. 2026 Q1 - Results - Earnings Call Presentation
4wSeekingAlpha
Cipher Pharmaceuticals Reports First Quarter Results
4wYahoo
Cipher Pharmaceuticals Announces Normal Course Issuer Bid
5wYahoo
Cipher Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call
5wYahoo
Unveiling Three Undiscovered Gems in Canada
6wYahoo
CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals’ Natroba™ (spinosad)
8wYahoo
Stifel Canada Lifts Cipher Pharmaceuticals Price Target By $1
11wYahoo
Cipher Pharmaceuticals Inc (CPHRF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
11wYahoo
Cipher Pharmaceuticals Inc (CPHRF) Q4 2025 Earnings Call Highlights: Revenue and Earnings Surge ...
11wYahoo
Cipher Pharmaceuticals Inc. (CPH:CA) Q4 2025 Earnings Call Transcript
12wSeekingAlpha
Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings
12wYahoo
Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call
13wYahoo
Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad)
18wYahoo
Discovering Canada's Undiscovered Gems In January 2026
19wYahoo
Undiscovered Gems in Canada to Explore This December 2025
23wYahoo
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
24wBenzinga
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
24wBenzinga